Cholesterol-lowering drugs — statins — may increase risk of diabetes and cognitive problems, says FDA

Some cholesterol-lowering drugs, or statins, received updated labels today from the U.S. Food and Drug Administration.

According to an FDA press release,

important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins are being announced today.

These products, when used with diet and exercise, help to lower a person’s “bad” cholesterol (low-density lipoprotein cholesterol). The products include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe). [Continue reading…]